

# **Pontine Glioma (DIPG):Drug Development Pipeline Study, H1 2018**

<https://marketpublishers.com/r/PED971DE215EN.html>

Date: February 2018

Pages: 65

Price: US\$ 895.00 (Single User License)

ID: PED971DE215EN

## **Abstracts**

The most comprehensive pipeline review “Diffuse Intrinsic Pontine Glioma (DIPG)- Drug Development Pipeline Study” provides in-depth analysis and update information on Diffuse Intrinsic Pontine Glioma (DIPG) pipeline drugs. Current status of all the drugs in the Diffuse Intrinsic Pontine Glioma (DIPG) pipeline is provided in the research work.

The report provides detailed analysis of Diffuse Intrinsic Pontine Glioma (DIPG) pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Diffuse Intrinsic Pontine Glioma (DIPG) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Diffuse Intrinsic Pontine Glioma (DIPG) industry.

Excerpts from- “Diffuse Intrinsic Pontine Glioma (DIPG)- Drug Development Pipeline Study”:

Pontine Glioma pipeline comprises of 24 drugs under development as of February 2018. Of these, 6 drugs are in Phase 1 and 3 drugs are in phase 1/2. Further, 8 drugs are in Phase 2 while 1 drug is in Phase 2/3 stage. In addition, 6 drugs are in Pre-Clinical Stage.

Eight drugs have been granted with Orphan drug designation by FDA/ EMA.

37 companies are developing the pipeline for Pontine Glioma. Of this, all the companies are developing one drug each and the Abbvie/ Seattle Genetics, Inc therapeutic candidate- ABT-414 is in Phase 2/3.

DIPG is an aggressive type of malignant glioma, arising from glioma tissue. It occurs around pons (brain stem) and impacts the cranial nerves. It also affects the long-tracks in the brain.

Symptoms include double-vision, unable to close eyelids, dropping a side of the face, difficulties in chewing, speech and walking. The solid tumor type is aggressive and accordingly, symptoms also rapidly develop.

As these are observed in the bottom area of the brain, they are tough to be treated. Currently, there is no cure for pontine glioma and any FDA / EMA approved treatment exists.

Scope:

- All latest industry developments and their impact on projects and companies
- Complete overview of global Diffuse Intrinsic Pontine Glioma (DIPG) therapy options and treatments
- The pipeline study reviews drug details for Diffuse Intrinsic Pontine Glioma (DIPG) by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Diffuse Intrinsic Pontine Glioma (DIPG) market
- Diffuse Intrinsic Pontine Glioma (DIPG) drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed

## Contents

### **1 TABLE OF CONTENTS**

1.1 LIST OF FIGURES

1.2 LIST OF TABLES

### **2 EXECUTIVE SUMMARY**

2.1 DISEASE OVERVIEW

2.2 PIPELINE SNAPSHOT

2.3 PIPELINE DRUGS BY PHASE

2.4 PIPELINE DRUGS BY COMPANY

2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

### **3 PONTINE GLIOMA- COMPANY WISE PIPELINE ANALYSIS**

3.1 ONCOCEUTICS, INC. PIPELINE, H1 2018

3.2 APEXIGEN INC. PIPELINE, H1 2018

3.3 ABBVIE INC PIPELINE, H1 2018

3.4 AROG PHARMACEUTICALS INC PIPELINE, H1 2018

3.5 ASTRAZENECA PLC PIPELINE, H1 2018

3.6 BOEHRINGER INGELHEIM PIPELINE, H1 2018

3.7 BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION PIPELINE, H1 2018

3.8 BURZYNSKI RESEARCH INSTITUTE PIPELINE, H1 2018

3.9 CELGENE CORPORATION PIPELINE, H1 2018

3.10 INSYS THERAPEUTICS INC PIPELINE, H1 2018

3.11 LOXO ONCOLOGY INC PIPELINE, H1 2018

3.12 MEDICENNA THERAPEUTICS CORP PIPELINE, H1 2018

3.13 MIDATECH PHARMA PIPELINE, H1 2018

3.14 MOLECULIN BIOTECH INC PIPELINE, H1 2018

3.15 NOVARTIS AG PIPELINE, H1 2018

3.16 KAZIA THERAPEUTICS LTD PIPELINE, H1 2018

3.17 PFIZER INC PIPELINE, H1 2018

3.18 SANOFI SA PIPELINE, H1 2018

3.19 SUMITOMO DAINIPPON PHARMA CO LTD PIPELINE, H1 2018

3.20 ZIOPHARM ONCOLOGY, INC. PIPELINE, H1 2018

3.21 Y-MABS THERAPEUTICS PIPELINE, H1 2018

3.22 DNATRIX, INC. PIPELINE, H1 2018

3.23 ONCORX PHARMACEUTICALS PIPELINE, H1 2018

3.24 CDG THERAPEUTICS, INC. PIPELINE, H1 2018

## **4 PONTINE GLIOMA PIPELINE DRUG SNAPSHOTS**

### **4.1 ONC201 DRUG DETAILS**

4.1.1 Snapshot

4.1.2 Drug Overview

4.1.3 Current Status

4.1.4 Mechanism of Action

4.1.5 Phase 2 trial details

### **4.2 APX 005M DRUG DETAILS**

4.2.1 Snapshot

4.2.2 Drug Overview

4.2.3 Current Status

4.2.4 Mechanism of Action

4.2.5 Phase 1 trial details

### **4.3 DEPATUXIZUMAB MAFODOTIN DRUG DETAILS**

4.3.1 Snapshot

4.3.2 Drug Overview

4.3.3 Mechanism of Action

4.3.4 Current Status

4.3.5 Phase 3 trial overview

4.3.6 Phase 2 trial overview

### **4.4 CRENOLANIB DRUG DETAILS**

4.4.1 Snapshot

4.4.2 Drug Overview

4.4.3 Mechanism of Action

4.4.4 Current Status

4.4.5 Phase 1 Details

### **4.5 AZD1775 DRUG DETAILS**

4.5.1 Snapshot

4.5.2 Drug Overview

4.5.3 Mechanism of Action

4.5.4 Current Status

4.5.5 Phase 1 Trial Details

4.5.6 Preclinical Phase Details

### **4.6 AFATINIB DRUG DETAILS**

- 4.6.1 Snapshot
- 4.6.2 Drug Overview
- 4.6.3 Mechanism of Action
- 4.6.4 Current Status
- 4.6.5 Phase 1 Trial Details
- 4.7 ANTINEOPLASTONS A10/AS2-1 DRUG DETAILS
  - 4.7.1 Snapshot
  - 4.7.2 Drug Overview
  - 4.7.3 Mechanism of Action
  - 4.7.4 Current Status
  - 4.7.5 Phase 2 trial Details
- 4.8 POMALIDOMIDE DRUG DETAILS
  - 4.8.1 Snapshot
  - 4.8.2 Drug Overview
  - 4.8.3 Mechanism of Action
  - 4.8.4 Current Status
- 4.9 CANNABIDIOL DRUG DETAILS
  - 4.9.1 Snapshot
  - 4.9.2 Drug Overview
  - 4.9.3 Mechanism of Action
  - 4.9.4 Current Status
- 4.10 LOXO-101 DRUG DETAILS
  - 4.10.1 Snapshot
  - 4.10.2 Drug Overview
  - 4.10.3 Mechanism of Action
  - 4.10.4 Current Status
  - 4.10.5 Phase 1 Results
- 4.11 MDNA55 DRUG DETAILS
  - 4.11.1 Snapshot
  - 4.11.2 Drug Overview
  - 4.11.3 Mechanism of Action
  - 4.11.4 Current Status
- 4.12 MTX110 DRUG DETAILS
  - 4.12.1 Snapshot
  - 4.12.2 Drug Overview
  - 4.12.3 Mechanism of Action
  - 4.12.4 Current Status
- 4.13 WP1066 DRUG DETAILS
  - 4.13.1 Snapshot

- 4.13.2 Drug Overview
- 4.13.3 Mechanism of Action
- 4.13.4 Current Status
- 4.13.5 Preclinical study results
- 4.14 PANOBINOSTAT DRUG DETAILS
  - 4.14.1 Snapshot
  - 4.14.2 Drug Overview
  - 4.14.3 Mechanism of Action
  - 4.14.4 Current Status
  - 4.14.5 Preclinical trial details
- 4.15 TRILEXIUM DRUG DETAILS
  - 4.15.1 Snapshot
  - 4.15.2 Mechanism of Action
  - 4.15.3 Current Status
  - 4.15.4 Preclinical phase
- 4.16 PIDILIZUMAB DRUG DETAILS
  - 4.16.1 Snapshot
  - 4.16.2 Drug Overview
  - 4.16.3 Mechanism of Action
  - 4.16.4 Current Status
  - 4.16.5 Phase 1 results
- 4.17 CABAZITAXEL DRUG DETAILS
  - 4.17.1 Snapshot
  - 4.17.2 Drug Overview
  - 4.17.3 Mechanism of Action
  - 4.17.4 Phase 1 details
- 4.18 DSP-7888 DRUG DETAILS
  - 4.18.1 Snapshot
  - 4.18.2 Drug Overview
  - 4.18.3 Mechanism of Action
  - 4.18.4 Current Status
  - 4.18.5 Phase 2 Trial Details
- 4.19 AD-RTS-HIL-12 DRUG DETAILS
  - 4.19.1 Snapshot
  - 4.19.2 Drug Overview
  - 4.19.3 Mechanism of Action
  - 4.19.4 Current Status
  - 4.19.5 Phase 1 Trial results
  - 4.19.6 Preclinical study results

#### 4.20 8H9 I-124 MAB DRUG DETAILS

- 4.20.1 Snapshot
- 4.20.2 Drug Overview
- 4.20.3 Mechanism of Action
- 4.20.4 Current Status
- 4.20.5 Phase 1 study results

#### 4.21 TASADENOTUREV DRUG DETAILS

- 4.21.1 Snapshot
- 4.21.2 Drug Overview
- 4.21.3 Mechanism of Action
- 4.21.4 Current Status

#### 4.22 ORX-101 DRUG DETAILS

- 4.22.1 Snapshot
- 4.22.2 Drug Overview
- 4.22.3 Mechanism of Action
- 4.22.4 Current Status

#### 4.23 AZURIN P28 DRUG DETAILS

- 4.23.1 Snapshot
- 4.23.2 Drug Overview
- 4.23.3 Mechanism of Action
- 4.23.4 Current Status

#### 4.24 NIVOLUMAB DRUG DETAILS

- 4.24.1 Snapshot
- 4.24.2 Drug Overview
- 4.24.3 Mechanism of Action
- 4.24.4 Current Status
- 4.24.5 Phase 2 trial details

### 5 RECENT DEVELOPMENTS IN PONTINE GLIOMA PIPELINE

5.1 MCG DRUG THERAPY BEING EMPLOYED FOR DIPG TREATMENT - JANUARY 2018

5.2 GLIOMA IN CHILDREN DIVIDED INTO DIVERSE SUBGROUPS THROUGH MOLECULAR META-ANALYSIS- SEPTEMBER 2017

5.3 WORLDWIDE CANCER RESEARCH AND BRAIN TUMOR CHARITY PARTNER TO FUND DIPG DRUG DEVELOPMENT- JANUARY 2018

5.4 HISTONE PROTEINS PRESENT HOPE OF TREATMENT FOR MALIGNANT BRAIN TUMOR IN CHILDREN- FEBRUARY 2017

## **6 APPENDIX**

### **6.1 ABOUT VPA RESEARCH**

### **6.2 SOURCES AND RESEARCH METHODOLOGY**



## List Of Figures

### LIST OF FIGURES

Figure 1: Pontine Glioma Pipeline by Phase, H1- 2018

Figure 2: Pontine Glioma Pipeline by Companies, H1- 2018

Figure 3: Company wise Pipeline Drug Phases, H1- 2018

Figure 4: Pontine Glioma Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

## List Of Tables

### LIST OF TABLES

Table 1: Pontine Glioma Pipeline by Phase, H1- 2018
Table 2: Pontine Glioma Pipeline by Companies, H1- 2018
Table 3: Pontine Glioma Pipeline by Mechanism of Action, H1- 2018
Table 4: ONCOCEUTICS, INC.- Pontine Glioma Pipeline, H1- 2018
Table 5: Apexigen Inc.- Pontine Glioma Pipeline, H1- 2018
Table 6: ABBVIE INC- Pontine Glioma Pipeline, H1- 2018
Table 7: AROG PHARMACEUTICALS INC- Pontine Glioma Pipeline, H1- 2018
Table 8: ASTRAZENECA PLC- Pontine Glioma Pipeline, H1- 2018
Table 9: BOEHRINGER INGELHEIM- Pontine Glioma Pipeline, H1- 2018
Table 10: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION- Pontine Glioma Pipeline, H1- 2018
Table 11: BURZYNSKI RESEARCH INSTITUTE- Pontine Glioma Pipeline, H1- 2018
Table 12: CELGENE CORPORATION- Pontine Glioma Pipeline, H1- 2018
Table 13: INSYS THERAPEUTICS INC- Pontine Glioma Pipeline, H1- 2018
Table 14: LOXO ONCOLOGY INC- Pontine Glioma Pipeline, H1- 2018
Table 15: MEDICENNA THERAPEUTICS CORP- Pontine Glioma Pipeline, H1- 2018
Table 16: MIDATECH PHARMA- Pontine Glioma Pipeline, H1- 2018
Table 17: MOLECULIN BIOTECH INC- Pontine Glioma Pipeline, H1- 2018
Table 18: NOVARTIS AG- Pontine Glioma Pipeline, H1- 2018
Table 19: KAZIA THERAPEUTICS LTD- Pontine Glioma Pipeline, H1- 2018
Table 20: PFIZER INC- Pontine Glioma Pipeline, H1- 2018
Table 21: SANOFI SA- Pontine Glioma Pipeline, H1- 2018
Table 22: SUMITOMO DAINIPPON PHARMA CO LTD- Pontine Glioma Pipeline, H1- 2018
Table 23: ZIOPHARM ONCOLOGY, INC.- Pontine Glioma Pipeline, H1- 2018
Table 24: Y-MABS THERAPEUTICS- Pontine Glioma Pipeline, H1- 2018
Table 25: DNATRIX, INC.- Pontine Glioma Pipeline, H1- 2018
Table 26: ONCORX PHARMACEUTICALS- Pontine Glioma Pipeline, H1- 2018
Table 27: CDG THERAPEUTICS, INC.- Pontine Glioma Pipeline, H1- 2018

## I would like to order

Product name: Pontine Glioma (DIPG):Drug Development Pipeline Study, H1 2018

Product link: <https://marketpublishers.com/r/PED971DE215EN.html>

Price: US\$ 895.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PED971DE215EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970